BG103867A - Cyanoguanidines as cell proliferation inhibitors - Google Patents

Cyanoguanidines as cell proliferation inhibitors

Info

Publication number
BG103867A
BG103867A BG103867A BG10386799A BG103867A BG 103867 A BG103867 A BG 103867A BG 103867 A BG103867 A BG 103867A BG 10386799 A BG10386799 A BG 10386799A BG 103867 A BG103867 A BG 103867A
Authority
BG
Bulgaria
Prior art keywords
stands
alkyl
hydrogen
trifluoromethyl
cyano
Prior art date
Application number
BG103867A
Other languages
Bulgarian (bg)
English (en)
Inventor
Erik Ottosen
Original Assignee
Leo Pharmaceutical Products Ltd.A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharmaceutical Products Ltd.A/S filed Critical Leo Pharmaceutical Products Ltd.A/S
Publication of BG103867A publication Critical patent/BG103867A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BG103867A 1997-05-29 1999-11-09 Cyanoguanidines as cell proliferation inhibitors BG103867A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9711119.9A GB9711119D0 (en) 1997-05-29 1997-05-29 Novel cyanoguanidines
PCT/DK1998/000195 WO1998054143A1 (en) 1997-05-29 1998-05-15 Cyanoguanidines as cell proliferation inhibitors

Publications (1)

Publication Number Publication Date
BG103867A true BG103867A (en) 2001-05-31

Family

ID=10813249

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103867A BG103867A (en) 1997-05-29 1999-11-09 Cyanoguanidines as cell proliferation inhibitors

Country Status (19)

Country Link
US (1) US6121297A (is)
EP (1) EP0984937A1 (is)
JP (1) JP2001526693A (is)
KR (1) KR20010013158A (is)
CN (1) CN1314890A (is)
AU (1) AU733093B2 (is)
BG (1) BG103867A (is)
BR (1) BR9809496A (is)
CA (1) CA2291489A1 (is)
EA (1) EA002037B1 (is)
EE (1) EE03871B1 (is)
GB (1) GB9711119D0 (is)
HK (1) HK1039116A1 (is)
HU (1) HUP0003150A3 (is)
IS (1) IS5229A (is)
NZ (1) NZ500702A (is)
PL (1) PL337091A1 (is)
SK (1) SK161199A3 (is)
WO (1) WO1998054143A1 (is)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4080300A (en) 1999-04-09 2000-11-14 Shionogi Bioresearch Corp. Cyanoguanidine compounds
AU1494702A (en) 2000-11-21 2002-06-03 Leo Pharma As Cyanoguanidine prodrugs
WO2002094265A1 (en) * 2001-05-24 2002-11-28 Leo Pharma A/S A method of modulating nf-$g(k)b activity
US20030045515A1 (en) * 2001-05-24 2003-03-06 Lise Binderup Combination medicament for treatment of neoplastic diseases
WO2002094813A1 (en) 2001-05-24 2002-11-28 Leo Pharma A/S Novel pyridyl cyanoguanidine compounds
US6642215B2 (en) * 2001-05-24 2003-11-04 Leo Pharma A/S Method of modulating NF-kB activity
US7253193B2 (en) 2002-05-17 2007-08-07 Leo Pharma A/S Cyanoguanidine prodrugs
ES2572777T3 (es) 2004-12-22 2016-06-02 Leo Pharma A/S Compuestos novedosos de cianoguanidina
US8173677B2 (en) 2007-09-26 2012-05-08 Gemin X Pharmaceuticals Canada Inc. Compositions and methods for effecting NAD+ levels using a nicotinamide phosphoribosyl transferase inhibitor
CA2701071C (en) 2007-09-26 2018-03-27 Gemin X Pharmaceuticals Canada Inc. Compositions and methods for effecting nad+ levels using a nicotinamide phosphoribosyl transferase inhibitor
CA2751495C (en) 2009-02-06 2013-08-20 Tianjin Hemay Bio-Tech Co., Ltd. Pharmaceutical compositions comprising a pyridyl cyanoguanidine and cyclodextrin and/or derivatives thereof
EP2611778B1 (en) 2010-09-03 2015-08-05 Forma TM, LLC. Guanidine compounds and compositions for the inhibition of nampt
US8859594B2 (en) 2010-10-26 2014-10-14 Tianjin Hemay Bio-Tech Co., Ltd. Polymorphs of N-(6-(4-chlorophenoxy)hexyl)-N′-cyano-N″-(4-pyridyl)guanidine, and preparation thereof and use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9219472D0 (en) * 1992-09-15 1992-10-28 Leo Pharm Prod Ltd Chemical compounds

Also Published As

Publication number Publication date
AU733093B2 (en) 2001-05-03
EA199901096A1 (ru) 2000-08-28
EP0984937A1 (en) 2000-03-15
EE9900551A (et) 2000-06-15
AU7638598A (en) 1998-12-30
HUP0003150A3 (en) 2002-10-28
SK161199A3 (en) 2000-06-12
EA002037B1 (ru) 2001-12-24
WO1998054143A1 (en) 1998-12-03
KR20010013158A (ko) 2001-02-26
US6121297A (en) 2000-09-19
HK1039116A1 (zh) 2002-04-12
GB9711119D0 (en) 1997-07-23
CN1314890A (zh) 2001-09-26
HUP0003150A2 (en) 2001-03-28
EE03871B1 (et) 2002-10-15
JP2001526693A (ja) 2001-12-18
PL337091A1 (en) 2000-07-31
BR9809496A (pt) 2000-06-20
CA2291489A1 (en) 1998-12-03
NZ500702A (en) 2001-07-27
IS5229A (is) 1999-10-26

Similar Documents

Publication Publication Date Title
HK1027562A1 (en) Cyanoguanidines as cell proliferation inhibitors
BG103867A (en) Cyanoguanidines as cell proliferation inhibitors
GB2369360A (en) 5-cyano-2-aminopyrimidine derivatives
EP1180518A4 (en) 5-PYRIDYLE-1,3-AZOLE COMPOUNDS, THEIR MANUFACTURING PROCESS AND THEIR USE
HK1053463A1 (en) Aminobenzophenones as inhibitors of il-1B and TNF-a.
ATE253545T1 (de) Biarylessigsäure-derivate und ihre verwendung als cox-2 inhibitoren
EP1248612A4 (en) NEW SUBSTANCES AND COMPOUNDS AS PROTEASE INHIBITORS
BG103964A (en) SUBSTITUTED PYRAZOLS AS p38 KINASE INHIBITORS
DE69928697D1 (de) Sulfohydroxamsäure and sulfohydroxamate und ihre verwendung als mek-inhibitoren
IL166271A0 (en) Pyrrolidinedione substituted piperidine phthalazone derivatives and pharmaceutical compositions containing the same
MA28279A1 (fr) Derives d'indole et utilisation de ceux-ci comme inhibiteurs de kinase, notamment des inhibiteurs de ikk2
GR3021015T3 (en) N-cyano-n'-pyridylguanidines as serotonin antagonists.
IS8377A (is) Arýlindenópyridín og arýlindenópyrimidín og notkun þeirra sem mótlyf A2A viðtaka adenósíns
HK1027568A1 (en) Cyanoguanidines as cell proliferation inhibitors
WO2002014281A8 (en) Pyridine derivatives as inhibitors of p38
HK1048303A1 (en) Aminobenzophenoses as inhibitors of il-1b and tnf -a.
MXPA06000986A (es) Compuestos.
MXPA02004441A (es) Derivados de isoxazol como inhibidores de la fosfodiesterasa.
TR199903159T2 (xx) Yeni �-Amino ve �-Azido karbonik asit t�revleri.
MXPA05012300A (es) Derivados de benzotiofeno de sulfamato como inhibidores de sulfatasa esteroidea.
MXPA06000988A (es) Derivados de nicotinamida utiles como inhibidores de pde4.
WO2004007498A3 (en) 3-phenyl analogs of toxoflavine as kinase inhibitors
UA74404C2 (uk) Похідні піридинзаміщених піразолопіридинів
YU23301A (sh) Postupak za dobijanje supstituisanih piridina
BG106154A (en) Carboxylic acid derivatives comprising aryl-substituted nitrogen heterocycles, methods for their production and their use as endothelin receptor antagonists